Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

TAK-632

National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

BenzothiazolesNitriles

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Identification of the Raf kinase inhibitor TAK‐632 and its analogues as potent inhibitors of necroptosis by targeting RIPK1 and RIPK3
Necroptosis is a form of programmed, caspase‐independent, cell death, mediated by receptor‐interacting protein kinases, RIPK1 and… 
2019
2019
N-(7-Cyano-6-(4-fluoro-3-(2-(3-(trifluoromethyl)phenyl)acetamido)phenoxy)benzo[ d]thiazol-2-yl)cyclopropanecarboxamide (TAK-632) Analogues as Novel Necroptosis Inhibitors by Targeting Receptor…
Necroptosis, a form of programmed cell death, plays a critical role in various diseases, including inflammatory, infectious, and… 
2019
2019
Metabolic Modifier Screen Reveals Secondary Targets of Protein Kinase Inhibitors within Nucleotide Metabolism.
Biosynthesis of the pyrimidine nucleotide uridine monophosphate (UMP) is essential for cell proliferation and is achieved by the… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2016
2016
Computational study on the unbinding pathways of B-RAF inhibitors and its implication for the difference of residence time: insight from random acceleration and steered molecular dynamics simulations…
B-RAF kinase is a clinically validated target implicated in melanoma and advanced renal cell carcinoma (RCC). PLX4720 and TAK-632… 
  • table 2
2016
2016
Design and synthesis of N-(4-aminopyridin-2-yl)amides as B-Raf(V600E) inhibitors.
B-Raf(V600E) was an effective target for the treatment of human cancers. Based on a pan-Raf inhibitor TAK-632, a series of N-(4… 
2014
2014
Abstract 4247: Characterization of the selective pan-RAF inhibitor TAK-632 with antitumor activity in BRAF inhibitor-resistant melanoma
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Melanoma is one of the deadliest and most aggressive forms… 
Highly Cited
2013
Highly Cited
2013
Discovery of a selective kinase inhibitor (TAK-632) targeting pan-RAF inhibition: design, synthesis, and biological evaluation of C-7-substituted 1,3-benzothiazole derivatives.
With the aim of discovering a selective kinase inhibitor targeting pan-RAF kinase inhibition, we designed novel 1,3-benzothiazole… 
Highly Cited
2013
Highly Cited
2013
Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
The mitogen-activated protein kinase (MAPK) pathway is particularly important for the survival and proliferation of melanoma… 
  • figure 1
  • figure 2
  • table 1
  • figure 4
  • table 2
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE